Skip to main content
. 2015 Sep 10;6(32):33612–33622. doi: 10.18632/oncotarget.5600

Figure 1. Decitabine increased sensitivity to cytotoxic drugs in chemoresistant AML cells.

Figure 1

Viability was measured by MTT assay in AML cells and patient samples Different AML cells A. were treated with decitabine for 72h. HL60 B., C. and D., HL60/ADR E., F. and G. and Kasumi-1 H., I. and J. were treated with different concentrations of harringtonine, adriamycin or cytarabine for 24h. Primary AML cells K. and L. were treated with 10μM adriamycin or cytarabine for 24h. (*P < 0.01, **P < 0.05).